Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis

Background/Aims A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD...

Full description

Bibliographic Details
Main Authors: Hyo Young Lee, Dae Won Jun, Hyun Jung Kim, Hyunwoo Oh, Waqar Khalid Saeed, Hyeongsik Ahn, Ramsey C. Cheung, Mindie H. Nguyen
Format: Article
Language:English
Published: The Korean Association of Internal Medicine 2019-03-01
Series:The Korean Journal of Internal Medicine
Subjects:
meta-analysis
non-alcoholic fatty liver disease
hydroxymethylglutaryl-coa reductase inhibitors
ezetimibe
Online Access:http://www.kjim.org/upload/pdf/kjim-2017-194.pdf

Internet

http://www.kjim.org/upload/pdf/kjim-2017-194.pdf

Similar Items